Compare FNUC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNUC | SCYX |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 60.4M |
| IPO Year | 2021 | 2014 |
| Metric | FNUC | SCYX |
|---|---|---|
| Price | $1.95 | $4.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 586.4K | 288.0K |
| Earning Date | 06-24-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $0.57 |
| 52 Week High | $2.82 | $5.62 |
| Indicator | FNUC | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 71.37 |
| Support Level | $1.92 | $0.67 |
| Resistance Level | $2.52 | $5.62 |
| Average True Range (ATR) | 0.24 | 0.30 |
| MACD | -0.04 | 0.13 |
| Stochastic Oscillator | 22.35 | 72.56 |
Frontier Nuclear and Minerals Inc is developing a U.S.-focused front-end nuclear fuel cycle company through a portfolio of U.S. uranium exploration and development projects in Wyoming, Colorado, and Utah, together with investments in next-generation uranium enrichment and small modular reactors. Frontier Nuclear is actively evaluating value-accretive investment opportunities in other sectors of the domestic U.S. nuclear fuel cycle. The group is developing a portfolio of critical minerals projects in America, Canada, and Namibia, including uranium, tantalum, cesium, and lithium. Its projects are Engo Valley, Pine Ridge, Shatford Lake, Snow Lake Lithium, and Tallahassee.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.